The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Tufan Erginbilgic says business deals to supply nuclear power for artificial intelligence could boost its fortunes ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

A multinational study shed light on which sites to scan for early signs of the disease, but scoring system was less sensitive ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Motivated by the belief that technology can drive positive changes, Artash Nath founded You-Oceans.com, a youth-led ...

Despite current warning labels, oseltamivir is not linked to increased risk for neuropsychiatric events in pediatric patients ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now esti ...